I thought it was fine. Nothing really new, but a couple of points I liked:
1) They expressed strong feelings that lympho would be approved and that they/Cardinal are gearing up.
2) It seems that there could be Euro distributor info coming in the not too distant future, and that terms could be very good.
3) Their take on short interest, we are aware, but really only concerned with executing the business plan.
4) Big Pharma is seeking them out to help because of their expertise in getting products through late trials/regulatory (hard to believe after troubles we have had in the past, but a new sheriff is in town now)
I think they are focused on really moving the business forward. I don't think they are worried about getting the share price up a few bucks on the short term; they see much bigger things long term.